RESUMEN
Atrial fibrillation (AF) is one of the most frequently seen arrhythmia. Optimal strategy of its treatment still remains a serious problem. The goal of the investigation was the evaluation of the efficacy of combined treatment of AF with Cordaron and ACE inhibitor Diroton (lizinopril) (D) in patients with chronic heart failure (CHF). 29 patients (32-78 years old) with persistive AF and CHF (II - III class NYHA) were under observation. The treatment with C 200 - 300 mg/day and D 5 -10mg/day for 12 weeks resulted in improvement of clinical status of the patients, improvement in functional class of CHF, decrease in frequency of recurrences of AF in comparison with patients who were not given ACE inhibitor. Ultrasound study showed that combined therapy increases myocardial contractility corrects left ventricular remodeling, maintains the sinus rhythm and improve prognoses in this category of the patients. The use of ACE inhibitior D in antiarrhythmic (antirecurrent) therapy together with C is optimal in patients with persistive AF CHF.
Asunto(s)
Amiodarona/uso terapéutico , Antiarrítmicos/uso terapéutico , Anticoagulantes/uso terapéutico , Fibrilación Atrial/complicaciones , Fibrilación Atrial/tratamiento farmacológico , Insuficiencia Cardíaca/tratamiento farmacológico , Insuficiencia Cardíaca/etiología , Warfarina/uso terapéutico , Adulto , Anciano , Femenino , Humanos , Masculino , Persona de Mediana Edad , Resultado del Tratamiento , Remodelación VentricularRESUMEN
In coronary patients with relatively intact myocardial function, tobanum increases physical stress tolerance and produces positive central hemodynamic shifts, while myocardial contractility is depressed insignificantly. In patients with low myocardial functional reserve, these parameters, on the contrary, deteriorate, particularly during exercise. Combined use of tobanum and corinfar in patients with impaired myocardial contractility controls cardio- and hemodynamic shifts and increases physical stress tolerance.